Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 17/20 | 0.82 |
| ▸ | PDE4A | P27815 | 13/20 | 0.82 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4923289 | 0.90 | PDE4B (1.00) | PDE4BPDE4APDE4DKDM4EALDH1A1 | |
| SCHEMBL4913248 | 0.90 | PDE4B (0.89) | PDE4BPDE4APDE4DKDM4EALDH1A1 | |
| SCHEMBL4046379 | 0.85 | PDE4B (0.72) | PDE4BPDE4APDE4DALDH1A1MEN1 | |
| SCHEMBL4916899 | 0.84 | PDE4B (0.82) | PDE4BPDE4APDE4DKDM4EALDH1A1 | |
| SCHEMBL4921988 | 0.84 | PDE4B (0.87) | PDE4BPDE4APDE4DKDM4EALDH1A1 | |
| SCHEMBL4918255 | 0.83 | PDE4B (1.00) | PDE4BPDE4APDE4DKDM4EALDH1A1 | |
| SCHEMBL4924655 | 0.82 | PDE4B (0.80) | PDE4BPDE4APDE4DKDM4EALDH1A1 | |
| SCHEMBL4916906 | 0.82 | PDE4B (0.87) | PDE4BPDE4APDE4DKDM4EALDH1A1 | |
| SCHEMBL4757623 | 0.82 | PDE4B (1.00) | PDE4BPDE4APDE4DKDM4EALDH1A1 | |
| SCHEMBL4924082 | 0.82 | PDE4B (0.79) | PDE4BPDE4APDE4DKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221096-A1 | Pyrido[3' ,2':4,5]Furo[3,2-d]Pyrimidine Derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-09-11 | — | — | US | disclosed |
| EP-1913003-A1 | NEW PYRIDO[3',2':4,5]FURO[3,2-d]PYRIMIDINE DERIVATIVES | Laboratorios Almirall, S.A. (ES) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017078-A1 | NEW PYRIDO[3',2':4,5]FURO[3,2-d]PYRIMIDINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221096-A1 | Pyrido[3' ,2':4,5]Furo[3,2-d]Pyrimidine Derivatives | NR1H2, CBR3, NR4A1 | PDE4B 4185/4885PDE4A 3960/4885PDE4D 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.